Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket

Author: Lisa Levin | December 13, 2022 08:54am

Gainers

  • Netcapital Inc. (NASDAQ:NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
  • Jiuzi Holdings, Inc. (NASDAQ:JZXN) shares rose 81.6% to $0.2689 in pre-market trading.
  • Magenta Therapeutics, Inc. (NASDAQ:MGTA) rose 51.3% to $1.74 in pre-market trading after the company highlighted updated data from the ongoing MGTA-117 Phase 1/2 dose-escalation trial at the American Society of Hematology 2022 Annual (ASH) Meeting.
  • Nova LifeStyle, Inc (NASDAQ:NVFY) rose 38.6% to $0.79 in pre-market trading after jumping more than 18% on Monday.
  • MediaCo Holding Inc (NASDAQ:MDIA) rose 34.8% to $1.47 in pre-market trading after the company said it has divested the assets of Fairway Outdoor LLC to Lamar Advertising Company for $78.6 million.
  • ACM Research, Inc. (NASDAQ:ACMR) shares rose 25.9% to $10.98 in pre-market trading.
  • MamaMancini's Holdings, Inc. (NASDAQ:MMMB) rose 25.4% to $1.58 in pre-market trading following better-than-expected Q3 results.
  • Ventyx Biosciences, Inc. (NASDAQ:VTYX) rose 22.8% to $35.11 in pre-market trading after gaining over 5% on Monday.
  • Starry Group Holdings, Inc. (NYSE:STRY) rose 22% to $0.1220 in pre-market trading.
  • Pardes Biosciences, Inc. (NASDAQ:PRDS) rose 21.7% to $1.40 in pre-market trading. JMP Securities initiated coverage on Pardes Biosciences with a Market Outperform rating and announced a price target of $9.
  • China Pharma Holdings, Inc. (NYSE:CPHI) shares rose 21.1% to $0.1701 in pre-market trading. China Pharma recently announced the acquisition of Dry Eye Disease Therapeutic Device Project.
  • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) rose 20.9% to $1.07 in pre-market trading after surging over 52% on Monday.
  • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) rose 20.7% to $0.5539 in pre-market trading after surging over 55% on Monday. Faraday Future Intelligent Electric recently appointed FF China CEO Xuefeng (XF) Chen as Global CEO of the company
  • Amesite Inc. (NASDAQ:AMST) rose 19.8% to $0.3715 in pre-market trading after jumping 32% on Monday.
  • Mirati Therapeutics, Inc. (NASDAQ:MRTX) climbed 15.9% to $47.99 in pre-market trading after the company announced U.S. FDA accelerated approval of KRAZATI as a targeted treatment option for patients with locally advanced or metastatic non-small cell lung cancer with a KRASG12C mutation.
  • Eargo, Inc. (NASDAQ:EAR) rose 15.4% to $0.71 in pre-market trading. Eargo and NationsBenefits announced a strategic partnership.
  • Longeveron Inc. (NASDAQ:LGVN) rose 13.2% to $3.78 in pre-market trading.
  • Centogene N.V. (NASDAQ:CNTG) rose 13% to $0.92 in pre-market trading after gaining over 8% on Monday.
  • Luokung Technology Corp. (NASDAQ:LKCO) rose 8.9% to $0.1989 in pre-market trading.
  • Gaotu Techedu Inc. (NASDAQ:GOTU) gained 6.6% to $1.78 in pre-market trading. Gaotu Techedu, last month, reported a third-quarter FY22 sales decline of 45.6% year-on-year to RMB606.2 million ($85.21 million).
  • AbCellera Biologics Inc. (NASDAQ:ABCL) surged 5.8% to $11.10 in pre-market trading.
  • Solid Power, Inc. (NASDAQ:SLDP) gained 5.6% to $2.79 in pre-market trading after declining around 6% on Monday.
  • Dingdong (Cayman) Limited (NYSE:DDL) gained 4.3% to $4.88 in pre-market trading after declining over 3% on Monday.
  • Pinterest, Inc. (NYSE:PINS) climbed 3.4% to $24.42 in pre-market trading. Piper Sandler upgraded Pinterest from Neutral to Overweight and raised the price target from $25 to $30.
  • Oracle Corporation (NYSE:ORCL) gained 2.6% to $83.36 in pre-market trading after the company reported better-than-expected results for its second quarter on Monday.


Don’t forget to check out our premarket coverage here .


Losers

  • Quotient Limited (NASDAQ:QTNT) fell 48.5% to $0.3528 in pre-market trading. Quotient announced intent to voluntary delist from the Nasdaq Global Market.
  • Argo Blockchain plc (NASDAQ:ARBK) shares fell 28.1% to $0.4952 in pre-market trading. Argo Blockchain recently announced a November operational update..
  • Ambrx Biopharma Inc. (NYSE:AMAM) shares fell 20.5% to $2.27 in pre-market trading after dipping 37% on Monday.
  • The Lion Electric Company (NYSE:LEV) fell 16.9% to $2.22 in pre-market trading. Lion Electric reported pricing of 19,685,040 unit offering at $2.54 per unit.
  • China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) fell 15.4% to $6.01 in pre-market trading after gaining around 115% on Monday.
  • Edible Garden AG Incorporated (NASDAQ:EDBL) fell 15.4% to $0.3625 in pre-market trading after jumping over 59% on Monday.
  • Hyperfine, Inc. (NASDAQ:HYPR) shares fell 15.3% to $1.04 in pre-market trading. Hyperfine, on December 6, committed to organizational restructuring designed to decrease costs, create streamlined organization to support business, and has terminated approximately 13% of its global workforce.
  • Adamas One Corp. (NASDAQ:JEWL) shares fell 12.8% to $4.14 in pre-market trading.
  • Engine Gaming and Media, Inc. (NASDAQ:GAME) fell 12.3% to $0.9282 in pre-market trading after jumping 95% on Monday. The company last Thursday announced it has entered into an agreement to combine with GameSquare Esports.
  • Getaround, Inc. (NYSE:GETR) fell 11.2% to $1.82 in pre-market trading after dropping 32% on Monday. Getaround recently announced closing of business combination with InterPrivate II Acquisition Corp.
  • Aptevo Therapeutics Inc. (NASDAQ:APVO) fell 10.7% to $3.49 in pre-market trading. Aptevo Therapeutics shares surged 14% on Monday after the company announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve AML patients.
  • Amprius Technologies, Inc. (NYSE:AMPX) fell 7.9% to $6.51 in pre-market trading.

Posted In: ABCL ACMR AMAM AMPX AMST APVO ARBK CJJD CNTG CPHI DDL EAR EDBL FFIE GAME GETR GOTU HYPR JEWL JZXN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist